SG/PUT/AMGEN/300/0.1/21.06.24 | Delayed Deutsche Boerse AG 10:08:50 03/06/2024 BST | ||
| 0.3 EUR | -23.08% |
|
| 1 month | -85.87% | ||
| 3 months | -84.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 0.3 | -23.08% |
| 31/05/24 | 0.39 | -23.53% |
| 30/05/24 | 0.51 | -30.14% |
| 29/05/24 | 0.73 | +35.19% |
| 28/05/24 | 0.54 | +68.75% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 10:08 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
Société Générale
|
| WKN | SQ73LU |
| ISIN | DE000SQ73LU5 |
| Date issued | 18/01/2023 |
| Strike | 300 $ |
| Maturity | 21/06/2024 (19 Days) |
| Parity | 10 : 1 |
| Emission price | 4.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.08 € |
|---|---|
| Lowest since issue | 0.17 € |
| Spread | 0.04 € |
| Spread % | 11.43% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant